Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octylonium bromide in irritable colon. II. Repeated oral administration

Sixty out-patients with acute or sub-acute irritable colon were randomly allocated to receive 3 daily doses of 100 mg tiropramide, 150 mg trimebutine maleate or 20 mg octilonium bromide, orally during 5 consecutive days. Before and after treatment, multiple colonic manometry was performed, monitorin...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 4(1986), 8 vom: 03., Seite 496-509
1. Verfasser: Galeone, M (VerfasserIn)
Weitere Verfasser: Benazzi, E, Bossi, M, Moise, G, Riva, A, Stock, F
Format: Aufsatz
Sprache:Italian
Veröffentlicht: 1986
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Comparative Study English Abstract Journal Article Randomized Controlled Trial Benzoates Parasympatholytics Quaternary Ammonium Compounds octylonium 26095-59-0 mehr... Tyrosine 42HK56048U Trimebutine QZ1OJ92E5R tiropramide R7S0904CN2
LEADER 01000naa a22002652 4500
001 NLM03696011X
003 DE-627
005 20231221140020.0
007 tu
008 231221s1986 xx ||||| 00| ||ita c
028 5 2 |a pubmed24n0124.xml 
035 |a (DE-627)NLM03696011X 
035 |a (NLM)3714757 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a ita 
100 1 |a Galeone, M  |e verfasserin  |4 aut 
245 1 0 |a Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octylonium bromide in irritable colon. II. Repeated oral administration 
246 3 3 |a Valutazione clinica e strumentale per manometria colonica multipla di tiropramide, trimebutina ed ottilonio bromuro in pazienti con colon irritabile. II. Somministrazione ripetuta per via orale 
264 1 |c 1986 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 09.07.1986 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Sixty out-patients with acute or sub-acute irritable colon were randomly allocated to receive 3 daily doses of 100 mg tiropramide, 150 mg trimebutine maleate or 20 mg octilonium bromide, orally during 5 consecutive days. Before and after treatment, multiple colonic manometry was performed, monitoring tonus, intensity and frequency of sinusoid contraction waves, transitories and vibrations, as well as the voluntary contraction capacity. Before treatment and after 2 and 5 days, the specific symptoms were also monitored, scored and recorded. Significant variations in tonus were not observed with any drug, but while tiropramide left unmodified the voluntary contractile ability, a significant inhibition was observed with trimebutine and, mainly, with octilonium. The overall power of spontaneous colonic contractions did not vary significantly with any drug. However, while with tiropramide a significant redistribution of muscular power was observed so as to increase propulsion waves and to decrease the ineffective transitory and vibrational contractions, with octilonium and trimebutine no clinically relevant redistribution of the power wasted in transient spasms was observed. Based on these observations, tiropramide was considered to be at least as effective an antispasmodic as octilonium and at least as effective a synchronizer as trimebutine, but was different from both reference drugs because it was the only one to act simultanously as both an antispasmodic and a synchronizer. The three drugs produced an improvement in each and all monitored symptoms as well as in the overall symptom intensity. Tiropramide, however, produced an improvement significantly faster, more progressively and to a greater extent than either reference drug.(ABSTRACT TRUNCATED AT 250 WORDS) 
650 4 |a Clinical Trial 
650 4 |a Comparative Study 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Benzoates  |2 NLM 
650 7 |a Parasympatholytics  |2 NLM 
650 7 |a Quaternary Ammonium Compounds  |2 NLM 
650 7 |a octylonium  |2 NLM 
650 7 |a 26095-59-0  |2 NLM 
650 7 |a Tyrosine  |2 NLM 
650 7 |a 42HK56048U  |2 NLM 
650 7 |a Trimebutine  |2 NLM 
650 7 |a QZ1OJ92E5R  |2 NLM 
650 7 |a tiropramide  |2 NLM 
650 7 |a R7S0904CN2  |2 NLM 
700 1 |a Benazzi, E  |e verfasserin  |4 aut 
700 1 |a Bossi, M  |e verfasserin  |4 aut 
700 1 |a Moise, G  |e verfasserin  |4 aut 
700 1 |a Riva, A  |e verfasserin  |4 aut 
700 1 |a Stock, F  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)  |d 1995  |g 4(1986), 8 vom: 03., Seite 496-509  |w (DE-627)NLM023961570 
773 1 8 |g volume:4  |g year:1986  |g number:8  |g day:03  |g pages:496-509 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_121 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 4  |j 1986  |e 8  |b 03  |h 496-509